Toddler's liver cancer vanishes after experimental CAR-T therapy
A 3-year-old boy with metastatic hepatoblastoma achieved a complete, durable remission after two infusions of an experimental GPC3-CAR T-cell therapy in the CARE study, with tumor regression on scans and a drop in AFP levels, and no systemic toxicity observed in this outpatient treatment. While highly promising, this is an early single-case result and further trials (CARE and IMPACT) are ongoing to assess safety and effectiveness in solid tumors.
